Partners Capital Investment Group’s Adaptive Biotechnologies ADPT Stock Holding History

Partners Capital Investment Group’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-150,935	Closed	-$4.24M	–	116
2021 Q4	$4.24M	Buy	150,935 +45,589	+43%	+$1.4M	0.2%	85
2021 Q3	$3.58M	Buy	105,346 +34,000	+48%	+$1.23M	0.16%	77
2021 Q2	$2.92M	Buy	71,346 +11,539	+19%	+$449K	0.13%	94
2021 Q1	$2.41M	Buy	59,807 +24,393	+69%	+$1.32M	0.11%	103
2020 Q4	$2.09M	Buy	+35,414	New	+$1.83M	0.12%	92

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Partners Capital Investment Group's ADPT Position: Q1 2022 in Review

Partners Capital Investment Group sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 150,935 shares — an estimated $4.24M sold.

Partners Capital Investment Group first reported a position in ADPT in Q4 2020 and held it in 5 quarters. The position peaked at $4.24M in Q4 2021. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

Partners Capital Investment Group reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
Partners Capital Investment Group sold 150,935 Adaptive Biotechnologies shares in Q1 2022, an estimated $4.24M.
Partners Capital Investment Group first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 5 quarters.
Partners Capital Investment Group's Adaptive Biotechnologies position peaked at $4.24M in Q4 2021.
221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on Partners Capital Investment Group's 13F filing for Q1 2022, filed 16 May 2022.